Q06187 (BTK_HUMAN) Homo sapiens (Human)
Tyrosine-protein kinase BTK UniProtKBInterProSTRINGInteractive Modelling
659 aa; Sequence (Fasta) ; (Isoform 2; ) 11 identical sequences
Sequence Features
521 | Proton acceptor. | ||
143 | Zinc. | ||
154 | Zinc. | ||
155 | Zinc. | ||
165 | Zinc. | ||
11 | L -> P (in XLA). VAR_006216 | ||
12 | K -> R (in XLA). VAR_006217 | ||
14 | S -> F (in XLA). VAR_006218 | ||
19 | K -> E (in XLA). VAR_008291 | ||
25 | F -> S (in XLA). VAR_006219 | ||
27 | K -> R (in XLA). VAR_008292 | ||
28 | R -> C (in XLA; no effect on phosphorylation of GTF2I). VAR_008293 | ||
28 | R -> H (in XLA; moderate; dbSNP:rs128620185). VAR_006220 dbSNP | ||
28 | R -> P (in XLA). VAR_006221 | ||
33 | T -> P (in XLA; severe; dbSNP:rs128620189). VAR_006222 dbSNP | ||
39 | Y -> S (in XLA). VAR_008960 | ||
40 | Y -> C (in XLA; dbSNP:rs1555980875). VAR_008294 dbSNP | ||
40 | Y -> N (in XLA). VAR_008295 | ||
61 | I -> N (in XLA). VAR_008296 | ||
64 | V -> D (in XLA). VAR_008297 | ||
64 | V -> F (in XLA). VAR_006223 | ||
82 | R -> K (in dbSNP:rs56035945). VAR_041676 dbSNP | ||
103 | Q -> QSVFSSTR (in XLA). VAR_006224 | ||
113 | V -> D (in XLA; dbSNP:rs128621190). VAR_006225 dbSNP | ||
115 | S -> F (in XLA). VAR_008298 | ||
117 | T -> P (in XLA). VAR_008299 | ||
127 | Q -> H (in XLA). VAR_008300 | ||
154 | C -> S (in XLA). VAR_008301 | ||
155 | C -> G (in XLA). VAR_008302 | ||
155 | C -> R (in XLA). VAR_008303 | ||
184 | T -> P (in XLA). VAR_008304 | ||
190 | P -> K (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions). VAR_041677 | ||
288 | R -> Q (in XLA; dbSNP:rs1555978277). VAR_008305 dbSNP | ||
288 | R -> W (in XLA; dbSNP:rs128621194). VAR_006227 dbSNP | ||
295 | L -> P (in XLA). VAR_006228 | ||
302 | G -> E (in XLA). VAR_006230 | ||
302 | G -> R (in XLA). VAR_008306 | ||
302 | Missing (in XLA). VAR_006229 | ||
307 | R -> G (in XLA; loss of activity; dbSNP:rs128621195). VAR_006231 dbSNP | ||
307 | R -> T (in XLA). VAR_008307 | ||
308 | D -> E (in XLA). VAR_008308 | ||
319 | V -> A (in XLA; moderate). VAR_008309 | ||
334 | Y -> S (in XLA; dbSNP:rs128621196). VAR_006232 dbSNP | ||
358 | L -> F (in XLA). VAR_006233 | ||
361 | Y -> C (in XLA; mild; dbSNP:rs28935478). VAR_006234 dbSNP | ||
362 | H -> Q (in XLA). VAR_006235 | ||
364 | H -> P (in XLA). VAR_006236 | ||
365 | N -> Y (in XLA). VAR_006237 | ||
366 | S -> F (in XLA). VAR_008310 | ||
369 | L -> F (in XLA). VAR_008311 | ||
370 | I -> M (in XLA). VAR_006238 | ||
372 | R -> G (in XLA). VAR_008312 | ||
408 | L -> P (in XLA; moderate; dbSNP:rs128621198). VAR_006239 dbSNP | ||
414 | G -> R (in XLA). VAR_008313 | ||
418 | Y -> H (in XLA; dbSNP:rs144079566). VAR_006240 dbSNP | ||
429 | I -> N (in XLA). VAR_006241 | ||
430 | K -> E (in XLA; loss of phosphorylation of GTF2I; dbSNP:rs128620184). VAR_006242 dbSNP | ||
430 | K -> R (in XLA). VAR_008314 | ||
445 | E -> D (in XLA). VAR_008315 | ||
462 | G -> D (in XLA). VAR_008316 | ||
462 | G -> V (in XLA). VAR_008317 | ||
476 | Y -> D (in XLA). VAR_006243 | ||
477 | M -> R (in XLA). VAR_006244 | ||
481 | C -> S (found in patients with chronic lymphocytic leukemia; unknown pathological significance; results in resistance to ibrutinib therapy; results in a protein that is reversibly inhibited by ibrutinib; disrupts the covalent binding between the enzyme and ibrutinib; dbSNP:rs1057519825 and dbSNP:rs1057519826). VAR_074309 dbSNP | ||
502 | C -> F (in XLA). VAR_006245 | ||
502 | C -> W (in XLA; dbSNP:rs41310709). VAR_006246 dbSNP | ||
506 | C -> R (in XLA; dbSNP:rs128621200). VAR_006247 dbSNP | ||
506 | C -> Y (in XLA). VAR_006248 | ||
508 | A -> D (in XLA). VAR_008318 | ||
509 | M -> I (in XLA). VAR_008319 | ||
509 | M -> V (in XLA). VAR_006249 | ||
512 | L -> P (in XLA). VAR_008961 | ||
512 | L -> Q (in XLA). VAR_008962 | ||
518 | L -> R (in XLA). VAR_008320 | ||
520 | R -> Q (in XLA; severe; prevents activation due to absence of contact between the catalytic loop and the regulatory phosphorylated residue; dbSNP:rs128621202). VAR_006251 dbSNP | ||
521 | D -> G (in XLA). VAR_008321 | ||
521 | D -> H (in XLA; severe). VAR_006252 | ||
521 | D -> N (in XLA; severe). VAR_006253 | ||
523 | A -> E (in XLA). VAR_008322 | ||
525 | R -> G (in XLA). VAR_008323 | ||
525 | R -> P (in XLA). VAR_006254 | ||
525 | R -> Q (in XLA; severe; disturbs ATP- binding; dbSNP:rs128620183). VAR_006255 dbSNP | ||
526 | N -> K (in XLA). VAR_006256 | ||
535 | V -> F (in XLA). VAR_008324 | ||
542 | L -> P (in XLA; growth hormone deficiency; dbSNP:rs128621203). VAR_006257 dbSNP | ||
544 | R -> G (in XLA). VAR_008963 | ||
544 | R -> K (in XLA). VAR_006258 | ||
559 | F -> S (in XLA). VAR_008325 | ||
562 | R -> P (in XLA; dbSNP:rs104894770). VAR_006259 dbSNP | ||
562 | R -> W (in XLA; dbSNP:rs128621204). VAR_006260 dbSNP | ||
563 | W -> L (in XLA; dbSNP:rs1555977474). VAR_008326 dbSNP | ||
567 | E -> K (in XLA; severe). VAR_006261 | ||
578 | S -> Y (in XLA). VAR_008964 | ||
581 | W -> R (in XLA; dbSNP:rs128621205). VAR_006262 dbSNP | ||
582 | A -> V (in XLA). VAR_006263 | ||
583 | F -> S (in XLA). VAR_008327 | ||
587 | M -> L (in XLA; mild). VAR_006264 | ||
589 | E -> D (in XLA). VAR_008328 | ||
589 | E -> G (in XLA; moderate; interferes with substrate binding; dbSNP:rs128621206). VAR_006265 dbSNP | ||
589 | E -> K (in XLA). VAR_008965 | ||
592 | S -> P (in XLA). VAR_006267 | ||
594 | G -> E (in XLA; mild; interferes with substrate binding). VAR_006268 | ||
594 | G -> R (in XLA; dbSNP:rs1555977339). VAR_006269 dbSNP | ||
598 | Y -> C (in XLA). VAR_006270 | ||
607 | A -> D (in XLA; mild; dbSNP:rs128621208). VAR_006271 dbSNP | ||
613 | G -> D (in XLA; mild; interferes with substrate binding and/or domain interactions; dbSNP:rs128621209). VAR_006272 dbSNP | ||
619 | P -> A (in XLA). VAR_008330 | ||
619 | P -> S (in XLA). VAR_006273 | ||
619 | P -> T (in XLA). VAR_008331 | ||
622 | A -> P (in XLA). VAR_008332 | ||
626 | V -> G (in XLA). VAR_008333 | ||
630 | M -> I (polymorphism, 35%). VAR_006274 | ||
630 | M -> K (in XLA; dbSNP:rs128621210). VAR_006275 dbSNP | ||
630 | M -> T (in XLA). VAR_008334 | ||
633 | C -> Y (in XLA). VAR_006276 | ||
641 | R -> C (in XLA). VAR_006277 | ||
641 | R -> H (in XLA; severe). VAR_006278 | ||
644 | F -> L (in XLA). VAR_008335 | ||
644 | F -> S (in XLA). VAR_006279 | ||
647 | L -> P (in XLA). VAR_006280 | ||
652 | L -> P (in XLA; dbSNP:rs128622212). VAR_006281 dbSNP | ||
135-171 | Btk-type. | ||
408-416 | ATP. | ||
260-280 | Missing (in XLA; severe). VAR_006226 | ||
5-133 | Pleckstrin homology domain IPR001849PF00169 | ||
141-167 | Zinc finger, Btk motif IPR001562PF00779 | ||
220-266 | SH3 domain IPR001452PF00018 | ||
281-362 | SH2 domain IPR000980PF00017 | ||
402-650 | Serine-threonine/tyrosine-protein kinase, catalytic domain IPR001245PF07714 |
Sequence Alignments
Experimental structures
Description | Oligo-state | Ligands | Structure | Range | Download | Assess |
---|---|---|---|---|---|---|
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dih... |
Heteromer | 4×N42; | 5j87 | |||
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4 | homo-4-mer | 4×ZN; 8×4IP; | 1bwn | |||
PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATE | homo-4-mer | 4×ZN; 4×4IP; | 1b55 | |||
Crystal structure of the human BTK kinase domain | homo-2-mer | 3p08 | ||||
The structure of human BTK kinase domain in complex with a covalent inhibitor | homo-2-mer | 2×GYL; | 5xyz | |||
CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OX... | homo-2-mer | 2×6MV; | 5jrs | |||
Crystal structure of Bruton's tyrosine kinase domain | homo-2-mer | 1k2p | ||||
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28C | homo-2-mer | 2×NA; 2×ZN; | 1btk | |||
Crystal structure of PH domain of Bruton's tyrosine kinase | homo-2-mer | 2×ZN; 2×4PT; | 2z0p | |||
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGAND | monomer | 1×GJD; | 6di1 | |||
BTK1 SOAKED WITH IBRUTINIB-Rev | monomer | 1×1E8; 2×DMS; | 5p9i | |||
CRYSTAL STRUCTURE OF BTK with CNX 774 | monomer | 1×7G8; | 5p9k | |||
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND | monomer | 1×GJG; | 6di0 | |||
'Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a D... | monomer | 1×83P; 2×PEG; 3×EDO; | 5u9d | |||
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydro... | monomer | 1×KLM; 6×EDO; | 6nfh | |||
Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib | monomer | 1×MZJ; 1×CL; | 6omu | |||
BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059 | monomer | 1×DMS; 1×7GB; | 5p9m | |||
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR | monomer | 1×GJ7; 1×DMS; | 6di5 | |||
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(... | monomer | 1×4US; 1×DMS; 2×EDO; | 5bq0 | |||
Bruton's tyrosine kinase (BTK) with GDC-0853 | monomer | 2×SO4; 8×EDO; 1×9AJ; | 5vfi | |||
Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinase | monomer | 1×IPA; 2×IMD; 1×4L6; 1×EDO; | 4z3v | |||
Discovery of affinity-based probes for Btk occupancy assay | monomer | 1×KHD; | 6n9p | |||
Crystal structure of ARQ 531 in complex with the kinase domain of BTK | monomer | 1×HRA; 2×IMD; 2×EDO; | 6e4f | |||
Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragment | monomer | 1×4RU; 1×IPA; 1×DMS; 2×IMD; | 4zly | |||
Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnoline | monomer | 1×IPA; 1×DMS; 2×IMD; 1×4RV; | 4zlz | |||
Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6... | monomer | 1×04K; | 3pj2 | |||
Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N... | monomer | 1×04L; | 3pj3 | |||
Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamin... | monomer | 2×LHL; | 3pj1 | |||
Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-m... | monomer | 1×03C; | 3piz | |||
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR | monomer | 1×DMS; 1×GJJ; | 6di9 | |||
BTK In Complex With Inhibitor | monomer | 1×LTJ; | 6o8i | |||
Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(... | monomer | 1×027; | 3pix | |||
BTK-inhibitor co-structure | monomer | 1×5WH; 1×5WE; | 5fbo | |||
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor | monomer | 9×NA; 2×SO4; 3×CL; 2×EDO; 1×4C9; | 4yhf | |||
'BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyr... | monomer | 1×KLP; 2×SO4; | 6nfi | |||
Crystal structure of BTK kinase domain complexed with R406 | monomer | 1×585; | 3piy | |||
Co-crystal structure of BTK kinase domain with Zanubrutinib | monomer | 1×IMD; 1×BA0; | 6j6m | |||
The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-contai... | monomer | 1×B43; | 3gen | |||
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mech... | monomer | 1×1N1; | 3k54 | |||
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND | monomer | 1×GJA; | 6di3 | |||
BTK1 COCRYSTALLIZED WITH IBRUTINIB | monomer | 1×8E8; | 5p9j | |||
BTK1 IN COMPLEX WITH CC 292 | monomer | 1×7G9; | 5p9l | |||
BTK IN COMPLEX WITH GDC-0834 | monomer | 1×GOL; 4×EDO; 1×2VL; | 5p9f | |||
BTK complex with compound 12 | monomer | 2×GOL; 1×DXM; 3×SO4; 1×FPZ; | 6bkw | |||
Brutons tyrosine kinase in complex with compound 50. | monomer | 1×EDO; 1×L9S; | 6nzm | |||
Structure of BTK with RN486 | monomer | 1×7G6; | 5p9g | |||
Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-... | monomer | 1×2V1; | 4ot6 | |||
Bruton's tyrosine kinase (BTK) with pyridazinone compound 23 | monomer | 2×GOL; 1×3YO; 2×SO4; 1×PG0; | 4rx5 | |||
Bruton's tyrosine kinase (BTK) with pyridazinone compound 9 | monomer | 2×GOL; 2×SO4; 1×PG0; 1×6XL; | 5kup | |||
Bruton's tyrosine kinase (BTK) with compound G-744 | monomer | 2×GOL; 2×SO4; 2×PG0; 1×9B1; | 5vgo | |||
BTK kinase domain with inhibitor 1 | monomer | 1×5WF; 1×5WE; 1×CL; | 5fbn | |||
BTK1 COCRYSTALLIZED WITH RN983 | monomer | 1×7G7; | 5p9h | |||
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1... | monomer | 1×GMQ; | 6hrp | |||
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymet... | monomer | 2×DMS; 1×3OV; | 4rfz | |||
BTK complex with compound 13 | monomer | 1×DY4; 1×GOL; 3×SO4; | 6bln | |||
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-... | monomer | 1×GMW; | 6hrt | |||
Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-... | monomer | 1×73T; | 5t18 | |||
Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl... | monomer | 1×2V2; 2×DMS; | 4otq | |||
Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazin... | monomer | 2×DMS; 1×481; | 4ot5 | |||
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815 | monomer | 1×BXM; 2×SO4; | 6aub | |||
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625 | monomer | 1×GOL; 1×BXJ; 2×SO4; | 6aua | |||
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1... | monomer | 2×DMS; 1×3OU; | 4rfy | |||
BTK complex with compound 7 | monomer | 1×DTJ; 3×SO4; 1×GOL; | 6bik | |||
Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin... | monomer | 1×2V3; 2×DMS; | 4otr | |||
Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinib | monomer | 1×1N1; | 3oct | |||
BTK complex with compound 10 | monomer | 3×SO4; 1×DVJ; | 6bke | |||
Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiper... | monomer | 1×BNB; | 6ep9 | |||
Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methy... | monomer | 1×3P0; | 4rg0 | |||
BTK complex with compound 11 | monomer | 1×DVD; 4×SO4; | 6bkh | |||
Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746 | monomer | 3×SO4; 1×746; 1×BME; | 3ocs | |||
BTK in complex with an inhibitor | monomer | 1×L0Z; | 6s90 | |||
Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834 | monomer | 3×SO4; 1×2VL; | 4otf | |||
Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-te... | monomer | 1×2P5; | 4nwm | |||
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(... | monomer | 1×4UQ; | 5bpy | |||
Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e | monomer | 1×9M3; | 5zz4 | |||
Solution Structures of the SH2 domain of Bruton's Tyrosine Kinase | monomer | 2ge9 | ||||
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURES | monomer | 1aww | ||||
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTURE | monomer | 1awx | ||||
NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structures | monomer | 1qly |
Homology models
Oligo-state | Ligands | QMEAN | Template | Range | Seq id (%) | Report | Download | Assess |
---|---|---|---|---|---|---|---|---|
monomer | 1×AU; | -1.42 | 4xi2.1.A | 98.21 | ||||
monomer | -1.92 | 1opl.2.A | 39.68 | |||||
monomer | -2.78 | 1y57.1.A | 38.62 | |||||
monomer | -2.68 | 2fo0.1.A | 39.77 |
Homology models built on isoform sequence
Isoform # | Oligo-state | Ligands | QMEAN | Template | Range | Seq id (%) | Report | Download | Assess |
---|---|---|---|---|---|---|---|---|---|
2 | monomer | 1×AU; | -1.42 | 4xi2.1.A | 98.21 | ||||
2 | monomer | -1.92 | 1opl.2.A | 39.68 | |||||
2 | monomer | -2.78 | 1y57.1.A | 38.62 | |||||
2 | monomer | -2.74 | 2fo0.1.A | 40.00 |